Background
Methods
Patient and clinical background
Culture techniques and culture media
Morphology of the resected original tumor and cultured cells
Growth characteristics
Chromosome analysis
Heterotransplantation
Tumor markers
Immunohistochemical stainings
Chemosensitivity assays
Results
Histopathology of the original tumor specimen
Establishment of the cell line
Morphology of the cultured cells
Growth characteristics
Chromosome analysis
Heterotransplantation
Tumor markers
Hormone receptors
Chemosensitivity
Drug | EC50 | PPC |
---|---|---|
(μg/mL)
|
(μg/mL)
| |
ACD | >0.1 | 0.08 |
ADM | 16.5 | 0.4 |
BLM | >1000 | 3.3 |
CBDCA | >300 | 37.1 |
CDDP | 23.2 | 8.5 |
CPA | >10 | 4.3 |
CPT-11 | 1.79 | 0.05 |
5-FU | 497 | 15.3 |
MMC | 6.5 | 2.4 |
MTX | >300 | 3 |
PTX | 5.1 | 11.8 |
VCR | 15 | 0.1 |
VLB | 16 | 0.15 |
VP-16 | 197 | 13 |
Discussion
Cell line | Age | Materials | Chromosome Number | DT | Transplantability | Immunotaining | Characteristics |
---|---|---|---|---|---|---|---|
#2774 (1978) | - | ascites | 66-68 | - | Yes | - | - |
- (1983) | 47 | ascites | 103 (51–402) | 74.4 | Yes | - | - |
OVK18 (1983) | 49 | ascites | 47 (mode) | 48 | Yes | - | ER(−), PgR(−) |
HMOA (1986) | 57 | ovarian tumor | 46-47 (mode) | 72, 58 | Yes | - | production of CA125 |
HNOA (1986) | 71 | transplanted tumor | 46-47 (mode) | 28, 24 | Yes | - | CA125(−) |
HOC-I (1989) | 40 | recurrent tumor | 46 (44–49) | 75 | Yes | ER(−) | ER(−), production of CA125, TPA |
COV362 (1993) | - | - | 69 (67–73) | - | - | - | - |
SIB-1 (1994) | 39 | pleural effusion | 46 (43–54) | - | - | HMFG-2, CA125 | serum free medium |
SNU-251 (1997) | 47 | ascites | - | 46 | - | - | CA125(−), CEA(−), p53, BRCA1, hMLH1 mutation(+) |
SNU-563 (1997) | 54 | ovarian tumor | - | 67 | - | - | p53 mutation(+) |
NOE (2007) | 46 | tumor fluid | 65-74 | - | Yes | - | ER(+) |
NOMH-1 | 44 | ovarian tumor | 73-80 | 273 | Yes | CA19-9, CEA, ER(−), PgR(−) | production of CA19-9, CEA, TPA |